Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. - Tarantino P; Li T; Ogayo ER; Rahman T; DiLullo MK; Patel A; El-Refai S; Abbott C; Li B; Boyle SM; Chen RO; Desai NV; et al. (JAMA oncology, 2026)